Lipocine (LPCN) Net Income towards Common Stockholders (2012 - 2025)

Lipocine (LPCN) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$3.2 million in Q3 2025.

• Quarterly Net Income towards Common Stockholders fell 43.63% year-over-year to -$3.2 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was -$7.3 million (down 86994.41% YoY) and the FY2024 annual result came in at $8352.0, up 100.05% from the prior year.
• Net Income towards Common Stockholders declined to -$3.2 million in Q3 2025, from -$2.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $12.6 million in Q4 2021 to a low of -$6.8 million in Q2 2021.
• A 5-year average of -$1.8 million and a median of -$2.6 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders surged 379.83% — and 2023, when it sank 176.07%.
• Tracing LPCN's Net Income towards Common Stockholders over 5 years: stood at $12.6 million in 2021, then plunged by 117.66% to -$2.2 million in 2022, then declined by 2.35% to -$2.3 million in 2023, then jumped by 178.09% to $1.8 million in 2024, then plunged by 278.82% to -$3.2 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$3.2 million (Q3 2025), -$2.2 million (Q2 2025), and -$1.9 million (Q1 2025), per Business Quant data.